Simulations Plus, Inc. (NASDAQ:SLP) declared a quarterly dividend on Thursday, January 10th, Wall Street Journal reports. Shareholders of record on Friday, January 25th will be given a dividend of 0.06 per share by the technology company on Friday, February 1st. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date is Thursday, January 24th.
Simulations Plus has increased its dividend by an average of 6.3% per year over the last three years and has raised its dividend annually for the last 2 consecutive years. Simulations Plus has a payout ratio of 60.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect Simulations Plus to earn $0.55 per share next year, which means the company should continue to be able to cover its $0.24 annual dividend with an expected future payout ratio of 43.6%.
Shares of SLP traded down $1.40 during mid-day trading on Thursday, reaching $18.98. The stock had a trading volume of 167,477 shares, compared to its average volume of 84,797. The firm has a market cap of $337.85 million, a P/E ratio of 37.96 and a beta of -0.55. Simulations Plus has a 12 month low of $14.25 and a 12 month high of $23.95.
A number of equities analysts recently weighed in on SLP shares. Zacks Investment Research upgraded shares of Simulations Plus from a “sell” rating to a “hold” rating in a research report on Wednesday. BidaskClub upgraded shares of Simulations Plus from a “hold” rating to a “buy” rating in a research report on Tuesday, October 16th.
In other Simulations Plus news, Director Walter S. Woltosz sold 18,500 shares of the stock in a transaction on Monday, October 29th. The shares were sold at an average price of $20.01, for a total transaction of $370,185.00. Following the completion of the transaction, the director now owns 5,399,408 shares in the company, valued at $108,042,154.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 31.57% of the stock is currently owned by corporate insiders.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
See Also: Why is insider trading harmful?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.